Clinical Trials

98 enrolled

Phase 1/2 Not yet recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT07225985 2026-03-06

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

50 enrolled

Lymphoid

Lymphoma, T-Cell

NCT07452458 2026-03-05

Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

Phase 3 Not yet recruiting

398 enrolled

CNS

Glioblastoma

NCT07441681 2026-03-02

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

Phase 3 Not yet recruiting

454 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07439484 2026-02-27

PRECISE

Phase NA Not yet recruiting

20 enrolled

Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8

NCT07082270 2026-02-19

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

21 enrolled

Plasma cell

Multiple Myeloma

NCT06827054 2026-02-18

Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids

20 enrolled

Other solid neoplasm

Hematopoietic and Lymphatic System Neoplasm

NCT06943664 2026-02-18

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

Phase 4 Not yet recruiting

27 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07281547 2026-02-18

Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain

25 enrolled

Gynecologic

Endometrial Neoplasms

NCT07377006 2026-02-18

Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer

Phase NA Not yet recruiting

108 enrolled

Prostatic Neoplasms

NCT05521698 2026-02-17

Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

80 enrolled

Non-Muscle Invasive Bladder Urothelial Carcinoma

NCT06224673 2026-02-13

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

36 enrolled

Triple Negative Breast Neoplasms

NCT07405086 2026-02-12

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

160 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT07365306 2026-01-26

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

43 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07363408 2026-01-23

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer

30 enrolled

Colorectal Neoplasms

NCT07349771 2026-01-20

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

72 enrolled

Hematopoietic and Lymphatic System Neoplasm

NCT07323641 2026-01-07

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Phase NA Not yet recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06816979 2025-12-22

Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07293403 2025-12-19

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

25 enrolled

Lymphoid

Lymphoma, T-Cell

NCT06492759 2025-12-16

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

29 enrolled

Triple Negative Breast Neoplasms

NCT07276360 2025-12-11

HypoRTCx-UG

Phase 3 Not yet recruiting

278 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07271355 2025-12-09

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

129 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Appendiceal Neoplasms, Colorectal Neoplasms

NCT07261657 2025-12-03

N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

8 enrolled

Sarcoma

Sarcoma, Synovial, Liposarcoma, Myxoid

NCT07191717 2025-11-10

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

42 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT07226544 2025-11-10

Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

31 enrolled

Carcinoma, Renal Cell

NCT07218692 2025-10-20

RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

35 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07037004 2025-09-23

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

62 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Carcinoma, Renal Cell

NCT07131007 2025-09-04

Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics

Not yet recruiting

2,000 enrolled

Tumor-Agnostic

Neoplasms

NCT07089940 2025-07-29

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

12 enrolled

Phase 1/2 Not yet recruiting

Pancreatic Neoplasms

NCT07042919 2025-06-29

Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

53 enrolled

Fibrosis, Carcinoma, Hepatocellular

NCT07020533 2025-06-13

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

LymphoidMyeloidOther hematologic neoplasm

46 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT06996119 2025-05-30

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

MyeloidOther hematologic neoplasm

15 enrolled

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06129851 2023-11-13

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

90 enrolled